Solutions For Healthcare Providers

Corneal Health Solutions

At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies that advance the existing standard of care, and enrich the lives and treatment alternatives for patients worldwide.

The iLink® Procedure

Transforming the Standard of Care for Progressive Keratoconus

iLink® corneal cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) riboflavin eye drops, combined with ultraviolet light from the KXL system to1:

  • Create new corneal collagen cross-links
  • Shorten and thicken collagen fibrils
  • Stiffen and strengthen the cornea

[Beshtawi2013/p451/col2/para1/lines10-14; p452/col1/para1/lines3-6; col2/para1/lines10-11; lines23-27]

Less Cross-Linking (Weaker).
Less Cross-Linking (Weaker)
More Cross-Linking (Stronger).
More Cross-Linking (Stronger)
Active Ingredient: Riboflavin 5’–phosphate Sodium.
Active Ingredient:
Riboflavin 5’–phosphate Sodium

Learn how iLink® corneal cross-linking can be used to slow or halt the progression of keratoconus and helps preserve vision in your patients.

View Info

The iDetect KC program makes advanced
topography more accessible than ever before.

Learn More

Explore Patient Resources for Keratoconus Treatment Options

View Patient Website

Find a Physician Performing the iLink® Procedure

Go to Physician Locator

Market Access Support

Looking for

Every patient deserves access to procedures that can help preserve their vision. iLink® corneal cross-linking helps patients avoid sight-threatening disease progression. That’s why GPS (Glaukos Patient Services) provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Learn More

Contact Us Today
to Integrate the iLink® Procedure Into Your

Explore additional information about iLink® in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.

Request More Info

"*" indicates required fields

This field is for validation purposes and should be left unchanged.


1. Beshtawi IM, O’Donnell C, Radhakrishnan H. Biomechanical properties of corneal tissue after ultraviolet-A-riboflavin crosslinking. J Cataract Refract Surg. 2013;39(3):451–462.

Please Select Your Country


Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.


Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.


1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022